AstraZeneca plans to highlight rare diseases as part of an $80 billion revenue push, as reported by the Financial Times.
FirstSquawk07/20, 12:00 PM
Related assets
Coming up for AZN
Explore next
Latest AZN news
Jin1008/17, 07:48 PM
Jin1008/17, 01:48 PM
Jin1008/05, 07:04 PM
Astrazeneca and Bristol Myers Squibb have no ongoing discussions regarding a potential transaction.